209 related articles for article (PubMed ID: 25400818)
1. Immunohistochemical characterization of brain-invasive meningiomas.
Backer-Grøndahl T; Moen BH; Arnli MB; Torseth K; Torp SH
Int J Clin Exp Pathol; 2014; 7(10):7206-19. PubMed ID: 25400818
[TBL] [Abstract][Full Text] [Related]
2. Microscopic anatomy of the brain-meningioma interface.
Nakasu S; Fukami T; Jito J; Matsuda M
Brain Tumor Pathol; 2005; 22(2):53-7. PubMed ID: 18095106
[TBL] [Abstract][Full Text] [Related]
3. Cathepsins B and L are markers for clinically invasive types of meningiomas.
Strojnik T; Zidanik B; Kos J; Lah TT
Neurosurgery; 2001 Mar; 48(3):598-605. PubMed ID: 11270551
[TBL] [Abstract][Full Text] [Related]
4. Novel histopathological classification of meningiomas based on dural invasion.
Murase M; Tamura R; Kuranari Y; Sato M; Ohara K; Morimoto Y; Yoshida K; Toda M
J Clin Pathol; 2021 Apr; 74(4):238-243. PubMed ID: 32546547
[TBL] [Abstract][Full Text] [Related]
5. Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas.
Okuducu AF; Zils U; Michaelis SA; Michaelides S; von Deimling A
Histopathology; 2006 Jun; 48(7):836-45. PubMed ID: 16722933
[TBL] [Abstract][Full Text] [Related]
6. CD44 expression in human meningiomas: an immunohistochemical analysis.
Lewy-Trenda I; Omulecka A; Janczukowicz J; Papierz W
Pol J Pathol; 2004; 55(1):33-7. PubMed ID: 15195704
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema.
Nordqvist AC; Smurawa H; Mathiesen T
J Neurosurg; 2001 Nov; 95(5):839-44. PubMed ID: 11702875
[TBL] [Abstract][Full Text] [Related]
9. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
10. Transient receptor potential vanilloid (TRPV) channel expression in meningiomas: prognostic and predictive significance.
Goutsou S; Tsakona C; Polia A; Moutafidi A; Zolota V; Gatzounis G; Assimakopoulou M
Virchows Arch; 2019 Jul; 475(1):105-114. PubMed ID: 31119368
[TBL] [Abstract][Full Text] [Related]
11. Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas.
von Randow AJ; Schindler S; Tews DS
Pathol Res Pract; 2006; 202(5):365-72. PubMed ID: 16563650
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
Tummalapalli P; Gondi CS; Dinh DH; Gujrati M; Rao JS
Int J Oncol; 2007 Jul; 31(1):5-17. PubMed ID: 17549400
[TBL] [Abstract][Full Text] [Related]
13. A role for matrix remodelling proteins in invasive and malignant meningiomas.
Jalali S; Singh S; Agnihotri S; Wataya T; Salehi F; Alkins R; Burrell K; Navab R; Croul S; Aldape K; Zadeh G
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):e16-28. PubMed ID: 24989599
[TBL] [Abstract][Full Text] [Related]
14. Differential Diagnosis of Meningeal SFT-HPC and Meningioma: Which Immunohistochemical Markers Should Be Used?
Macagno N; Figarella-Branger D; Mokthari K; Metellus P; Jouvet A; Vasiljevic A; Loundou A; Bouvier C
Am J Surg Pathol; 2016 Feb; 40(2):270-8. PubMed ID: 26448189
[TBL] [Abstract][Full Text] [Related]
15. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
16. Progression of astrocytomas and meningiomas: an evaluation in vitro.
Maes L; Kalala JP; Cornelissen M; de Ridder L
Cell Prolif; 2007 Feb; 40(1):14-23. PubMed ID: 17227292
[TBL] [Abstract][Full Text] [Related]
17. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
18. MIB-1 staining index of pediatric meningiomas.
Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
[TBL] [Abstract][Full Text] [Related]
19. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
Puripat N; Loharamtaweethong K
Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
